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Although cancer immunotherapy can lead to durable outcomes, the percentage of patients who
respond to this disruptive approach remains modest to date. Encouragingly, nanotechnology
can enhance the efficacy of immunostimulatory small molecules and biologics by altering their
co-localization, biodistribution, and release kinetics.Awakening the Immune System
Although the research community has made great inroads into
understanding the underlying etiology of cancer, our ability to
confer durable responses to patients remains rather limited.
The complexity of cancer aside, a major obstacle impeding our
progress has been the widespread emphasis on cancer as a
cell-autonomous disease. Few biologists would study gill phys-
iology by removing a fish fromwater, yet we routinely interrogate
cancer cells outside of their natural habitat, discounting the
importance of the tumor microenvironment. In addition to stro-
mal cells and extracellular matrix, immune cells greatly impact
disease initiation, progression, and invasion.
Indeed, the type, density, and location of immune cells within
tumors predict patient survival as well as, if not better than,
traditional histopathological methods. This so-called ‘‘immune
contexture’’—most notably the presence of CD8+CD45RO+
T cells and TH1 cells—is associated with a good prognosis
across at least 20 different cancer types (Fridman et al., 2012).
Accordingly, oncologists are eager to arouse exhausted immune
cells, and clinical data confirm that stimulating a patient’s natural
antitumor immune response can cure relapsed, refractory pa-
tients with difficult-to-treat cancers who have exhausted other
treatment options (Topalian et al., 2011).
Challengingly, tumors can evade immune surveillance. Conse-
quently, most immunotherapies, particularly those directed
against solid tumors, have thus far benefited only a minority of
patients. For this reason, facilitating antitumor immune cells to
overcome the activation energy barrier presented by the immuno-
suppressive tumor microenvironment is an area of active investi-
gation. Emerging preclinical and clinical data suggest that delivery
of immunostimulatorymolecules fromnanoparticles and scaffolds
can rouse the immune system with greater rigor than delivery of
these same molecules in solution, leading to improved antitumor
immunity and survival outcomes. Accordingly, biologists and
engineers areworking to improve our understanding ofwhich cells
and pathways should be perturbed tomaximize efficacy andwhat
tools are most appropriate to perturb them as desired.
The Killer App for Nanomedicine?
Nanoparticles are synthetic particles (generally derived from
polymers, lipids, or metals) with sizes on the nanometer scale,which confers properties that bridge bulk and molecular struc-
tures. Such nanoparticles can be loaded with therapeutic com-
pounds to achieve concentrated local drug delivery with poten-
tial for sustained release when biodegradable carriers are used.
Their high surface-area-to-volume ratio enables them to be
coated with various ligands (e.g., antibodies or aptamers) that
can facilitate interaction with cognate molecules, including re-
ceptors present on the surface of target cells. Although nanopar-
ticles can improve the pharmacokinetic properties of their drug
payloads (Chow and Ho, 2013), their ability to target cancer cells
specifically and efficiently has proven somewhat elusive. Target-
ing nanoparticles to specific receptors on cancer cells augments
cellular uptake but not tumor localization, which is governed by
passive accumulation through leaky vasculature. In contrast,
leukocytes can actively traffic to tumors along chemokine gradi-
ents, rendering these cells the ultimate ‘‘targeted’’ therapy.
Delivery of immunostimulatory drugs to antitumor immune
cells may be a more efficient tactic to eradicate tumors than
delivery of cytotoxic drugs to cancer cells (Figure 1). While the
ability to concentrate nanoparticles within tumors upon sys-
temic administration remains a challenge, immune cells prolifer-
ate extensively upon activation. As a consequence, unlike for
cancer cells, successful payload delivery to even a small fraction
of immune cells can achieve robust antitumor efficacy. More-
over, tumors are heterogeneous and ever evolving, so drugs
that are designed to kill cancer cells directly by targeting cell-
intrinsic pathways inherently select for resistant clones that
lead to relapse. In contrast, immune cells can generate a coordi-
nated and adaptive antitumor response with capacity for mem-
ory that is not achievable using any other therapeutic modality.
Improving the Efficacy of Cancer Vaccines
Dendritic cells (DCs) are critical initiators of adaptive immune re-
sponses and are thus extremely relevant targets for anticancer
nanomedicines. Co-administration of antigen and adjuvant as
free drugs can result in delivery of antigen to someDCs and adju-
vant to others. Delivery of antigen in the absence of adjuvant
induces immunologic tolerance, thereby inhibiting robust anti-
tumor responses. Co-encapsulation of antigen and adjuvant in
a common particle enables co-delivery of both components to
the same DC, leading to improved induction of antigen-specificCell 161, April 9, 2015 ª2015 Elsevier Inc. 201
Figure 1. Applications of Nanotechnology
Clockwise from bottom left: nanocarriers can be
used to (1) deliver cancer vaccine antigens and
adjuvants to dendritic cells, (2) stimulate T cells
directly as artificial antigen presenting cells, (3)
concentrate immunostimulatory compounds in the
immunosuppressive tumor microenvironment,
and (4) deliver supportive drugs to T cells in the
circulation. (Image credit to Mohammad H. Saleh.)CD8+ T cells, which are critical mediators of antitumor immunity.
Sustained antigen release from a particle within DCs can further
enhance cytolytic T lymphocyte (CTL) priming in vitro by extend-
ing antigen presentation (Audran et al., 2003). Such particles
serve as antigen reservoirs, thereby mimicking both prime and
boost injections following a single administration.
As yet, the induction of robust CD8+ T cell responses in large
animal models has not been achieved using traditional protein
vaccine-based approaches, which have primarily elicited hu-
moral B cell responses. Excitingly, preliminary studies suggest
that nanoparticle-based vaccines may confer cross-priming
efficacy in non-human primates and humans similar to that
observed in mice. Should such findings be validated in larger co-
horts, then nanovaccines would serve as an important break-
through for the development of vector-free vaccines (Irvine
et al., 2013).
Owing to their pathogen-like size, nanoparticles are readily
taken up by antigen-presenting cells, such as DCs, which are
natural phagocytes. As a consequence, even untargeted
nanoparticles improve the uptake—which often correlates with
antitumor efficacy—of cancer vaccines relative to their soluble
forms. Altering particle size, hydrophobicity, and surface charge,
as well as conjugating targeting ligands, can further enhance up-
take efficiency (Cruz et al., 2012). Targeting nanoparticles to DCs
has proven much more feasible than targeting nanoparticles to
cancer cells. This difference is rooted in physics as much as in202 Cell 161, April 9, 2015 ª2015 Elsevier Inc.biology. First, owing to the fenestrated
architectures of secondary lymphoid
organs, nanoparticles naturally accumu-
late in these structures—particularly the
spleen—which are populated by many
DCs. Second, secondary lymphoid or-
gans do not exhibit the physical barriers
to entry that are characteristic of solid
tumors, such as elevated interstitial pres-
sure and impaired diffusion caused by
unusually dense extracellular matrix.
Of note, the subset of DC targeted is
critical to defining the induction and regu-
lation of immune responses (Ueno et al.,
2011). Plasmacytoid DCs can be con-
verted from toleragenic to innate immu-
nostimulatory upon uptake of Toll-like
receptor (TLR) 7 and/or 9 agonists. To
achieve adaptive responses, distinct sub-
sets of classical DCs can be targeted
by nanoparticles derived from poly(lac-
tic-co-glycolic acid) (PLGA)—a biode-gradable, FDA-approved polymer—to which antibodies are
coupled. The C-type lectin receptor on the surface of the DC
that is targeted by the antibody defines the type of immune
response produced. For example, targeting of DC-SIGN, DEC-
205, DNGR-1, and Langerin favors CD8+ T cell cellular (TH1) re-
sponses, whereas targeting of DCIR2 favors CD4+ T cell and B
cell humoral (TH2) responses (Cruz et al., 2012). Vaccine potency
may be maximized by targeting multiple DC subsets, thereby
inducing both cellular and humoral immune responses (Ueno
et al., 2011).
In addition to delivering information regarding specificity
and activity to DCs, some investigators have considered the
design of artificial antigen-presenting cells (aAPCs) that can
cross-prime antigen-specific CD8+ T cells directly. Synthetic
aAPCs are particles to which proteins required for T cell activa-
tion—such as MHC-epitope or agonist anti-CD3 (Signal 1 to
the T cell receptor) and agonist anti-CD28 (co-stimulatory
Signal 2)—have been conjugated. Manipulating particle shape
and geometry revealed that aAPC activity correlates with aspect
ratio (Sunshine et al., 2014). Mechanistically, CD8+ T cells
migrate preferentially to the long axis of ellipsoidal aAPCs, and
this extended length of contact increases T cell proliferation
and, consequently, tumor prevention.
These data not only have relevance to design parameters
for future aAPCs but also provide insights into the funda-
mental biology of DC-T cell interactions. Indeed, the result was
unexpected, as high aspect ratio has previously been associated
with increased particle internalization by non-phagocytic cells. In
addition to nanoparticles, scaffolds can be used to vaccinate
against cancer. Scaffolds similarly offer practical and functional
advantages over conventional DC-based vaccines, which
require isolation, ex vivo manipulation, and reintroduction of a
patient’s DCs.
Scaffolds: Customized Microenvironments
Polymeric scaffolds and hydrogels can be implanted or injected
to generate a modular, tailored local microenvironment that can
co-localize inflammatory cytokines, tumor antigen, and immune
danger signals in situ. For example, incorporation of the chemo-
kine GM-CSF, autologous tumor lysate, and the TLR9 agonist
CpG-oligonucleotide into a subcutaneously implanted porous
PLGA scaffold promotes recruitment and activation of DCs, re-
sulting in regression of established local and distant tumors (Ali
et al., 2009). The observed potency is attributed to the persistent
presence of antigen and adjuvant signaling in the depot, which
is not attainable upon delivery of soluble vaccine components
that diffuse away fairly rapidly. This exciting scaffold-based
approach is currently being investigated in a phase I clinical trial
(NCT01753089). To avoid the need for surgical implantation, an
injectable spontaneously assembling scaffold has been devised
(Kim et al., 2015). Specifically, mesoporous silica rods with high
aspect ratios form macroporous structures that provide a
favorable microenvironment for DCs, which subsequently traffic
to lymph nodes and provoke adaptive immune responses.
Scaffolds can similarly be used to improve the function of
adoptively transferred T cells by providing a supportive immuno-
logic microenvironment. Adoptive cell transfer (ACT), particularly
upon introduction of chimeric antigen receptors into T cells
(Maude et al., 2014), can lead to sustained remissions in
hematologic malignancies. Solid tumors, however, establish a
concentrated immunosuppressive microenvironment that ham-
pers the efficacy of ACT. Transplantation of lymphocytes in
biodegradable polymeric scaffolds can sustain expansion and
release of tumor-reactive T cells at tumor resection sites and
enhance their antitumor potency (Stephan et al., 2015). Scaf-
fold-derived T cells reduce residual disease and relapse much
more effectively than free T cells administered systemically or
locally. Such depots provide proof of concept for localized
delivery of cells, in addition to small molecules and biologics.
Localized immunotherapy is particularly well suited for treatment
of inoperable or incompletely removed tumors to prevent local
recurrence (Stephan et al., 2015), and its effects can have wide-
spread implications.
Localized Nanoimmunotherapy: Focal Impact
Achieving a robust local antitumor effect—as previously
observed for the radiation-induced ‘‘abscopal effect’’—can
generate a systemic antitumor immune response that can erad-
icate disseminated disease, including metastases situated in
sites generally thought to be tumor cell havens in the context
of traditional systemic therapy (Marabelle et al., 2013). Lipo-
somes can be used to anchor immunomodulatory compounds,
such as immunostimulatory nucleic acids and biologics (Kwong
et al., 2013), prior to intratumoral injection. Such particles restrictthe biodistribution of these compounds and prolong their reten-
tion at the tumor site. In so doing, localized nanoimmunotherapy
reduces systemic toxicity and thus improves the therapeutic
window of extremely potent immunostimulatory molecules while
still promoting systemic antitumor immunity (Kwong et al., 2011).
Delivering Tx to T Cells in Circulation
Immunoengineering also enables drug delivery directly to T cells.
The conjugation of nanoparticles loaded with supportive com-
pounds to the surface of adoptively transferred T cells leads to
persistent autocrine-like signaling among these ‘‘pharmacytes’’
(Stephan et al., 2010). This approach again demonstrates the
impact of nanotechnology relative to administration of free drug
and represents a paradigm that can be applied more broadly
than the ACT-supportive scaffold described above, as it does
not necessitate surgical implantation. Ideally, one would be
able to deliver such adjuvant drug-containing nanoparticles to
T cells upon systemic administration, enabling a generalized
approach that does not require ex vivo cell manipulation for
each patient. Excitingly, liposomes to which targeting ligands—
antibody fragments or cytokines—have been conjugated can
target drugdelivery to adoptively transferredTcells in vivo (Zheng
et al., 2013). Future work will likely enable targeted delivery to
endogenous T cells and, ultimately, other cell types as well.
Concentrating Catalysis
In addition to delivering small molecules, oligonucleotides, anti-
gens, and cytokines, nanoparticles can be used to concentrate
enzymes in vivo. For example, particles can be used to degrade
neutrophil extracellular traps (NETs). NETs are extracellular DNA
structures that,when formed intravascularly, cansequester circu-
lating tumor cells and thereby promote metastasis. Digesting
NETs with free DNase is relatively inefficient at inhibiting metas-
tasis (Cools-Lartigue et al., 2013), while DNase-coated nanopar-
ticles vastly improve therapeutic efficacy (J. Park, R.W. Wysocki,
Z. Amoozgar, M.S.G., and M. Egeblad, unpublished data).
Looking Ahead
Moving forward, the field of immunoengineering will benefit from
a broader adoption of novel tools that permit multiplex analysis
of cell type (multiplexed ion beam imaging), cell activation state
(mass cytometry), and soluble mediators of stimulation/inhibition
(Luminex) in the tumor microenvironment and circulation
following perturbation. By allowing for interrogation of several-
fold more parameters simultaneously than conventional meth-
odologies, such as flow cytometry and ELISA, such tools will
yield insights into the coordination of the highly complex immune
system. A comprehensive understanding of the downstream
impacts of our interventions, including expression of co-stimula-
tory/inhibitory ligands and production of immunoregulatory
cytokines, will enable rational product revision for improved
therapeutic outcomes.
Beyond enhancing our appreciation of the cellular and
biochemical constituents of the tumor microenvironment, we
will benefit from an increased consideration of the physical
microenvironment in the tumor, as well as its draining lymph no-
des (Swartz and Lund, 2012). Indeed, extracellular matrix serves
as a physical mediator of immunosuppression by preventingCell 161, April 9, 2015 ª2015 Elsevier Inc. 203
penetration of immune cells into the tumor core (Salmon and
Donnadieu, 2012). Immunoengineering can be used to alter the
physical microenvironment of tumors, for example, by modifying
peritumoral extracellular matrix (Kanapathipillai et al., 2012).
To this end, in addition to enablingmore thorough descriptions
of immune cell function (reading), advanced technologies can
be used to create physical lymphoid-like structures to study
and manipulate immune cell function (writing). Improving the
reproducibility of formulation and fabrication methods is critical,
as manufacturing represents perhaps the greatest obstacle con-
fronting the clinical translation of nanodevices. Controlled pro-
duction can minimize polydispersity. For example, 3D printing
is revolutionizing the field of regenerative medicine, and it has
the potential to influence cancer immunoengineering similarly.
Initially, this technology will likely be applied to produce defined,
improved scaffolds for vaccine applications or supportive ACT.
In the years ahead, it could be used to create implantable artifi-
cial tertiary lymphoid structures, which possess defined zones
for specialized immune cells and are important to long-term can-
cer patient survival (Fridman et al., 2012).
Transplantable lymphoid-like organoids can already be engi-
neered tomanifest discrete compartments for particular immune
cells, which generate functional humoral and cellular responses
to vaccination (Suematsu and Watanabe, 2004). 3D printing will
allow for deposition of specific cytokines, immune cells, and
matrix with unprecedented accuracy. This advance will have
relevance not only to translational biology but also to basic
immunology, as engineered scaffolds can enhance our under-
standing of the biochemical and physical microenvironments
that alter the balance between tolerance and rejection (Swartz
et al., 2012).
By concentrating the delivery of their payloads, nanoparticles
permit the use of considerably lower doses of immunostimula-
torymolecules to achieve a given response and thereby enhance
the safety profiles of these drugs (Irvine et al., 2013). Still, thema-
terials from which nanodevices are created can inherently pro-
voke a host response, so meaningful safety parameters must
be defined, such as serum levels of type I interferons and IL-6.
Unlike for prophylactic vaccines, such responses are likely
acceptable to cancer patients and may even be beneficial in
stimulating antitumor immunity, but they must be well under-
stood nonetheless. Encouragingly, tocilizumab (anti-IL6R) has
been used to manage cytokine-release syndrome successfully
in the acute setting (Maude et al., 2014). Placing an emphasis
on the development of safe biomaterials will facilitate earlier
translation of immunoengineered products into patients. Data
gleaned from patients will be more informative than anything
that can be derived from preclinical models.
Emerging evidence confirms that cancer immunotherapies,
which can generate adaptive and durable responses, yield
much more robust antitumor effects when they are formulated
in nanoparticles or scaffolds than when they are administered
as free drugs. Cancer immunoengineering is thus a promising
area worthy of further consideration and investigation. It is hoped
that this piece will stimulate basic biologists to engage bioengi-
neers and to articulate the questions that they would like to see204 Cell 161, April 9, 2015 ª2015 Elsevier Inc.addressed with innovative technologies. In addition to its thera-
peutic potential, immunoengineering provides a valuable tool for
dissecting fundamental biology.
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